Technical analysis of Aclaris Therapeutics, Inc. (ACRS): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions.
Price Performance
| 1 month | -15.69% |
| 3 months | +18.22% |
| Year-to-date | +76.74% |
| 1 year | +193.92% |
| 3 years | -28.40% |
| 5 years | -70.70% |
52-Week Range
| 52-week High | $6.60 |
| 52-week Low | $1.74 |
| Avg Volume (90d) | 1.9M |
Technical Indicators
| SMA 50 | $5.79 |
| SMA 200 | $4.32 |
| Beta | 0.68 |
| 30-day Volatility (annualised) | 54.3% |
| Price vs SMA 50 | -8.1% |
| Price vs SMA 200 | +23.2% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $2.52 | |
| 2025-11 | $2.83 | +12.3% |
| 2025-12 | $3.01 | +6.4% |
| 2026-01 | $3.51 | +16.6% |
| 2026-02 | $2.87 | -18.2% |
| 2026-03 | $3.75 | +30.7% |
| 2026-04 | $4.34 | +15.7% |
| 2026-05 | $4.55 | +4.8% |
| 2026-06 | $5.29 | +16.3% |
| 2026-07 | $5.20 | -1.7% |
| 2026-08 | $6.05 | +16.3% |
| 2026-09 | $5.32 | -12.1% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-15 | | |
| 2026-09-15 | $-0.02 | |
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | | |
Price
| Price | $5.32 |
| Market Cap | $743M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 6.25 |
| EV / EBITDA | -11.22 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 3.46 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -5.19 |